AAV2/9 Enables Superior Germ Cell Transduction in Mouse Testes
Frontiers in Bioscience-Landmark · 2025
DOI: 10.31083/fbl46354 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2025. Verfasst von Bangguo Wu und 2 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drugs and Devices, Shanghai Institute for Biomedi…. Hauptthemen laut MEDLINE: Dependovirus, Testis, Transduction, Genetic, Genetic Vectors. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
In contemporary gene therapy research, recombinant adeno-associated virus (rAAV) has emerged as a pivotal delivery vehicle due to its favorable safety profile and capacity for sustained transgene expression. The most commonly utilized rAAV variants are hybrid vectors constructed by packaging the AAV2 genome within the capsid proteins of alternative serotypes (e.g., AAV1, AAV5, AAV8, or AAV9). This chimeric design combines the stable genomic integration and long-term expression characteristics inherent to AAV2 with the distinct tissue tropisms conferred by different capsid serotypes. Consequently, these engineered rAAVs exhibit enhanced organ-targeting specificity, enabling more efficient and selective gene delivery to desired tissues while minimizing off-target effects.
Methods
To identify the optimal hybrid vector for germ cell-directed gene delivery in mice, ten distinct chimeric AAV variants were generated by pseudotyping the AAV2 genome with diverse capsid proteins, followed by microinjection into seminiferous tubules via the efferent ducts. Transduction efficiency was comparatively evaluated at 4 weeks post-injection.
Results
We demonstrated that AAV2/9 mediated robust and widespread enhanced green fluorescent protein (EGFP) expression in the mouse testis. Through immunofluorescence assays, we demonstrated that AAV2/9 demonstrated the capability to express in nearly all testicular cells, with remarkable efficiency and durability.
Conclusions
AAV2/9 demonstrated superior efficacy as a gene delivery vector for murine testicular germ cells without observable adverse effects on testicular development or spermatogenesis. This favorable safety profile, combined with high transduction efficiency establishes AAV2/9 as a promising candidate for therapeutic gene transfer to testicular germ cells. Collectively, our study identifies AAV2/9 as a premier vector for germ cell-directed gene therapy, providing crucial preclinical evidence to inform capsid selection for treating male infertility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drugs and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, School of Pharmacy, Fudan Univers…
- Department of Urology, Shanghai Tenth People's Hospital, Tongji University, 200040 Shanghai, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wu, B., Guo, Y., & Li, R. (2025). AAV2/9 Enables Superior Germ Cell Transduction in Mouse Testes. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl46354
Vancouver
Wu B, Guo Y, Li R. AAV2/9 Enables Superior Germ Cell Transduction in Mouse Testes. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl46354
BibTeX
@article{Wu2025,
author = {Wu, Bangguo and Guo, Yadong and Li, Runsheng},
title = {AAV2/9 Enables Superior Germ Cell Transduction in Mouse Testes},
journal = {Frontiers in Bioscience-Landmark},
year = {2025},
doi = {10.31083/fbl46354}
}
EUVIMED